In one retrospective analysis, a single-institution series of 17 patients with advanced PSCC received a complex regimen of chemotherapy (paclitaxel, ifosfamide, and cisplatin) plus nimotuzumab (anti-EGFR) and toripalimab (anti-PD1) [40]. The gene discussed is EGFR; the disease is squamous cell carcinoma of penis.